Similar articles

• Triple-Hormone-Receptor Agonist Retatrutide for Obesity.

  Elfeki MA, Alkhouri N. Elfeki MA, et al. N Engl J Med. 2023 Oct 26;389(17):1629. doi: 10.1056/NEJMc2310645. N Engl J Med. 2023. PMID: 37888926 No abstract available.
• Triple-Hormone-Receptor Agonist Retatrutide for Obesity.

  Bisson A, Fauchier G, Fauchier L. Bisson A, et al. N Engl J Med. 2023 Oct 26;389(17):1628. doi: 10.1056/NEJMc2310645. N Engl J Med. 2023. PMID: 37888925 No abstract available.
• Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.

  Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Jastreboff AM, et al. N Engl J Med. 2023 Aug 10;389(6):514-526. doi: 10.1056/NEJMoa2301972. Epub 2023 Jun 26. N Engl J Med. 2023. PMID: 37366315 Clinical Trial.
• Retatrutide showing promise in obesity (and type 2 diabetes).

  Doggrell SA. Doggrell SA. Expert Opin Investig Drugs. 2023 Jul-Dec;32(11):997-1001. doi: 10.1080/13543784.2023.2283020. Epub 2023 Nov 24. Expert Opin Investig Drugs. 2023. PMID: 37947489 Review.
• Direct effects of sex steroid hormones on adipose tissues and obesity.

  Mayes JS, Watson GH. Mayes JS, et al. Obes Rev. 2004 Nov;5(4):197-216. doi: 10.1111/j.1467-789X.2004.00152.x. Obes Rev. 2004. PMID: 15458395 Review.